Related Experiment Video

Updated: Jun 23, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

Secretory phospholipase A2 in patients with coronary artery disease

Luciana Moreira Lima1, Maria das Graças Carvalho, Cirilo Pereira da Fonseca Neto

  • 1Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos. 6627, Belo Horizonte, Minas Gerais, CEP 31270-901, Brazil.

Journal of Thrombosis and Thrombolysis
|May 19, 2009
PubMed

Insights

Elevated secretory phospholipase A2 (sPLA2) activity strongly correlates with coronary artery disease (CAD) severity. Higher sPLA2 levels were independently associated with severe atheromatosis in patients undergoing coronary angiography.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Medical Diagnostics

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality worldwide.
  • Atheromatosis, the buildup of plaque in arteries, is a hallmark of CAD.
  • Identifying reliable biomarkers for CAD severity is crucial for patient management.

Purpose of the Study:

  • To investigate the association between secretory phospholipase A2 (sPLA2) activity and the extent of atheromatosis in patients with CAD.
  • To determine if sPLA2 activity is an independent predictor of severe coronary stenosis.

Main Methods:

  • Analysis of plasma sPLA2 activity in 123 patients undergoing coronary angiography.
  • Patients were categorized into control (normal arteries), mild/moderate atheromatosis (30-70% stenosis), and severe atheromatosis (>70% stenosis) groups.
  • Multiple logistic regression analysis adjusted for various cardiovascular risk factors and biomarkers.

Main Results:

  • Plasma sPLA2 activity was significantly elevated in patients with mild/moderate and severe atheromatosis compared to controls.
  • sPLA2 activity was markedly higher in the severe atheromatosis group.
  • sPLA2 was identified as an independent predictor of severe CAD, even after adjusting for multiple confounding factors.

Conclusions:

  • Secretory phospholipase A2 activity is significantly correlated with the severity of atheromatosis in coronary artery disease.
  • sPLA2 may serve as a valuable independent biomarker for identifying patients with severe CAD.
  • Further research into the role of sPLA2 in atherogenesis is warranted.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...